Pablo J. Cagnoni, President of Research and Development at Incyte, completed a block sale of company stock on March 17, 2026, disposing of 18,667 shares of common stock at $94.24 per share for aggregate proceeds of roughly $1.76 million. At the time of the reported disposition, Incyte shares were trading near $92.95, having delivered a total return of 52.87% over the prior 12 months.
On the same day as the sale, Cagnoni exercised stock options entitling him to acquire an identical total — 18,667 shares — through two separate option tranches. One tranche covered 7,166 shares with an exercise price of $61.18 per share; the other tranche covered 11,501 shares with an exercise price of $64.25 per share. The combined cash value of those option exercises was reported as $1,177,355.
Following these transactions, Cagnoni's direct share ownership stands at 234,800 shares of Incyte common stock. That figure includes 229,661 shares issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.
An InvestingPro analysis cited in reports indicates that Incyte's shares remain undervalued on a Fair Value basis, and the company is described as maintaining a healthy balance sheet. The analysis and balance-sheet observations were presented alongside the disclosure of the insider transaction; no company earnings or revenue results were highlighted in the disclosure of these moves.
Regulatory and market developments affecting Incyte have been mixed. In Europe, the European Commission granted approval for Zynyz as a treatment for squamous cell carcinoma of the anal canal (SCAC), which the announcement notes represents the first systemic treatment option for advanced SCAC in Europe. This approval follows a positive opinion from the European Medicines Agency.
By contrast, in the United States the Food and Drug Administration issued a Complete Response Letter regarding Incyte's application to expand the Zynyz label for lung cancer. The CRL cited compliance issues at a third-party facility as the reason for the agency's response.
On the brokerage front, Jefferies adjusted its rating on Incyte stock to Hold from Buy, raising concerns tied to the impending expiration of Jakafi's patent in 2028. Stifel, however, kept a Buy rating on the shares despite the FDA setback.
Separately, the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion for Olumiant, a medicine developed in collaboration with Eli Lilly, for use in adolescent patients with alopecia areata. That recommendation is one of the regulatory actions noted in the recent company-related updates.
These insider transactions and the string of regulatory updates present a combination of corporate-finance activity and external developments for investors to weigh. The sale and option exercises by a senior R&D executive are recorded alongside regulatory approvals in Europe and a regulatory rejection in the U.S., plus divergent analyst ratings and patent-timing concerns cited by at least one broker. The net effect on valuation perspectives and investor positioning is reflected in the InvestingPro Fair Value commentary and the company's reported balance-sheet health.